1-20 of 110
Lei Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy

Yifan Liu, Hongying Wang, Xinyu Zhao, Jiashen Zhang, Zhiling Zhao, Xia Lian, Juan Zhang, Feng Kong, Tao Hu, Ting Wang, Xiaohua Li, Lei Wang, Dapeng Wang, Chunling Li, Huiwen Luan, Xiaoli Liu, Chunyan Wang, Yun Jiang, Xiaomin Li, Fangmin Li, Shuhao Ji, Yaopeng Wang, Zunling Li
Journal: Cancer Research
Cancer Res CAN-22-3115.
https://doi.org/10.1158/0008-5472.CAN-22-3115
Published: 28 July 2023
View article titled, Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
Open the PDF for Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy in another window
Includes: Supplementary data
Journal Articles

AKT Blocks SIK1-Mediated Repression of STAT3 to Promote Breast Tumorigenesis

Zicheng Sun, Qiwei Jiang, Bing Gao, Xiaomei Zhang, Lang Bu, Lei Wang, Ying Lin, Wei Xie, Jie Li, Jianping Guo
Journal: Cancer Research
Cancer Res (2023) 83 (8): 1264–1279.
https://doi.org/10.1158/0008-5472.CAN-22-3407
Published: 14 April 2023
View article titled, AKT Blocks SIK1-Mediated Repression of STAT3 to Promote Breast Tumorigenesis
Open the PDF for AKT Blocks SIK1-Mediated Repression of STAT3 to Promote Breast Tumorigenesis in another window
Includes: Supplementary data
Journal Articles

Abstract CT076: Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis

Yongqian Shu, Yueyin Pan, Ping Lu, Yi Jiang, Jingdong Zhang, Xiaohong Wu, Yuanhu Yao, Lin Shen, Yi Ba, Zhiyong He, Yuxian Bai, Jianhua Chen, Guohua Yu, Yanyan Peng, Hongqian Wu, Lei Wang, Liyun Li, Jianming Xu
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT076.
https://doi.org/10.1158/1538-7445.AM2023-CT076
Published: 14 April 2023
View article titled, Abstract CT076: Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis
Journal Articles

Abstract 4451: Developing a PROTAC-based NR4A1 degrader for melanoma cancer therapy

Rohan Master, Yuewan Luo, Yufeng Xiao, Daohong Zhou, Lei Wang, Guangrong Zheng, Weizhou Zhang
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4451.
https://doi.org/10.1158/1538-7445.AM2023-4451
Published: 04 April 2023
View article titled, Abstract 4451: Developing a PROTAC-based NR4A1 degrader for melanoma cancer therapy
Journal Articles

Abstract 961: HER2-low expression in patients with advanced or metastatic solid tumors

Burak Uzunparmak, Cara Haymaker, Gabriela Raso, Chen Zhu, Serena Masciari, Lei Wang, Bryce Kirby, Heather Lin, Aysegul Gorur, Ann-Marie Cimo, Amber Kennon, Qingqing Ding, Andrea Palmieri, Gabriele Elizabeth Urschel, Ying Yuan, Guoxin Feng, Yasmeen Rizvi, Aisha Hussain, Vivek Subbiah, Timothy Anthony Yap, Jordi Rodon-Ahnert, Sarina Anne Piha-Paul, David S. Hong, Funda Meric-Bernstam, Ecaterina E. Dumbrava
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 961.
https://doi.org/10.1158/1538-7445.AM2023-961
Published: 04 April 2023
View article titled, Abstract 961: HER2-low expression in patients with advanced or metastatic solid tumors
Journal Articles

Abstract 5347: Selective targeting deacetylase 3 (HDAC3) and HDAC8 by PROTACs

Yufeng Xiao, Seth Hale, Nikee Awasthee, Xuan Zhang, Yi Liu, Zhiguang Huo, Dongwen Lyu, Lei Wang, Weizhou Zhang, Megan Mosteiro, Daiqing Liao, Guangrong Zheng
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5347.
https://doi.org/10.1158/1538-7445.AM2023-5347
Published: 04 April 2023
View article titled, Abstract 5347: Selective targeting deacetylase 3 (HDAC3) and HDAC8 by PROTACs
Journal Articles

Abstract 2326: Proteolysis-targeting chimera against NR4A1 for cancer immunotherapy

Lei Wang, Yufeng Xiao, Rohan P. Master, Zeng Jin, Urvi M. Patel, Yuewan Luo, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 2326.
https://doi.org/10.1158/1538-7445.AM2023-2326
Published: 04 April 2023
View article titled, Abstract 2326: Proteolysis-targeting chimera against NR4A1 for cancer immunotherapy
Journal Articles

Abstract 2923: JAB-X1800: A potent immunostimulatory antibody-drug conjugate (iADC) targeting CD73

Yang Ye, Guiqun Yang, Hongling Wang, Xin Sun, Yanping Wang, Fashun Yan, Lei Wang, Wei Long
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 2923.
https://doi.org/10.1158/1538-7445.AM2023-2923
Published: 04 April 2023
View article titled, Abstract 2923: JAB-X1800: A potent immunostimulatory antibody-drug conjugate (iADC) targeting CD73
Journal Articles

Abstract 2637: Novel folate receptor alpha-directed antibody-drug conjugate PRO1184 demonstrates broad antitumor activity with a promising safety profile in preclinical models

Lei Wang, Haidong Liu, Chang Zhou, Tae Han, Baiteng Zhao, Zhu Chen
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 2637.
https://doi.org/10.1158/1538-7445.AM2023-2637
Published: 04 April 2023
View article titled, Abstract 2637: Novel folate receptor alpha-directed antibody-drug conjugate PRO1184 demonstrates broad antitumor activity with a promising safety profile in preclinical models
Journal Articles

Abstract 571: Angiopoietin-like 4 as a potential therapeutic target for clear cell renal carcinoma

Zeng Jin, Umasankar De, Lei Wang, Jeremy Kleberg, Weizhou Zhang, Ryan Kolb
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 571.
https://doi.org/10.1158/1538-7445.AM2023-571
Published: 04 April 2023
View article titled, Abstract 571: Angiopoietin-like 4 as a potential therapeutic target for clear cell renal carcinoma
Journal Articles

Abstract 6573: Drug Combo: A unique resource for efficient phase 1 trial design with manually curated MTD and DLT

Lei Wang, Shijun Zhang, Lai Wei, Yuxi Zhu, Dwight Owen, Lang Li
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 6573.
https://doi.org/10.1158/1538-7445.AM2023-6573
Published: 04 April 2023
View article titled, Abstract 6573: Drug Combo: A unique resource for efficient phase 1 trial design with manually curated MTD and DLT
Journal Articles

Abstract P2-01-07: Combination of pyrotinib with trastuzumab, taxanes and platinum as neoadjuvant therapy in patients with HER2-positive early or locally advanced breast cancer: a multicenter phase II trial

Hao Zhou, Lei Wang, Lei Wang, Zhaoji Guo
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P2-01-07.
https://doi.org/10.1158/1538-7445.SABCS22-P2-01-07
Published: 01 March 2023
View article titled, Abstract P2-01-07: Combination of pyrotinib with trastuzumab, taxanes and platinum as neoadjuvant therapy in patients with HER2-positive early or locally advanced breast cancer: a multicenter phase II trial
Journal Articles

Abstract P3-07-25: Efficacy and safety of neoadjuvant pertuzumab biosimilar TQB2440, trastuzumab and docetaxel in HR negative, HER2 positive breast cancer: a single-arm trial

Jiang Wu, Jing Yu, Yuqing Yang, Xinxin Wen, Jixin Yang, Hongliang Wei, Xiaolong Xu, Yike Li, Liu Yang, Dongdong Xu, Lei Wang, Yijia Wang, Wen Ma, Nanlin Li
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P3-07-25.
https://doi.org/10.1158/1538-7445.SABCS22-P3-07-25
Published: 01 March 2023
View article titled, Abstract P3-07-25: Efficacy and safety of neoadjuvant pertuzumab biosimilar TQB2440, trastuzumab and docetaxel in HR negative, HER2 positive breast cancer: a single-arm trial
Journal Articles

Abstract LB566: Class 1 HDAC inhibition induces antitumor immunity by NF-kB-mediated enhanced metabolic fitness and generation of unique effector function enriched memory CD8 T cell subtype

Nour Shobaki, Pankaj Gaur, Rahul Nadre, Vivek Verma, Peter Ordentlich, Lei Wang, Nazli Jafarzadeh, Wael Traboulsi, Mikayel Mkrtichyan, Seema Gupta, Samir N. Khleif
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): LB566.
https://doi.org/10.1158/1538-7445.AM2022-LB566
Published: 15 June 2022
View article titled, Abstract LB566: Class 1 HDAC inhibition induces antitumor immunity by NF-kB-mediated enhanced metabolic fitness and generation of unique effector function enriched memory CD8 T cell subtype
Journal Articles

Abstract 1405: Novel ADC platform delivers promising in vivo activity and safety

Haidong Liu, Wenke Qi, Lei Wang, Guobao Wang, Xinyue Chen, Julia Gavrilyuk, Tae Han, Baiteng Zhao, Xiao Shang
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1405.
https://doi.org/10.1158/1538-7445.AM2022-1405
Published: 15 June 2022
View article titled, Abstract 1405: Novel ADC platform delivers promising <em>in vivo</em> activity and safety
Journal Articles

Abstract 1759: PRO1160, a novel CD70-directed antibody-drug conjugate, demonstrates robust anti-tumor activity in mouse models of renal cell carcinoma and non-Hodgkin lymphoma

Lei Wang, Haidong Liu, Xiao Shang, Tae Han, Baiteng Zhao
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1759.
https://doi.org/10.1158/1538-7445.AM2022-1759
Published: 15 June 2022
View article titled, Abstract 1759: PRO1160, a novel CD70-directed antibody-drug conjugate, demonstrates robust anti-tumor activity in mouse models of renal cell carcinoma and non-Hodgkin lymphoma
Journal Articles

Abstract 1758: The preclinical pharmacology of PRO1102, a novel exatecan-based HER2-directed antibody-drug conjugate with robust anti-tumor activity

Lei Wang, Haidong Liu, Xiao Shang, Tae H. Han, Baiteng Zhao
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1758.
https://doi.org/10.1158/1538-7445.AM2022-1758
Published: 15 June 2022
View article titled, Abstract 1758: The preclinical pharmacology of PRO1102, a novel exatecan-based HER2-directed antibody-drug conjugate with robust anti-tumor activity
Journal Articles

Abstract 1085: PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, demonstrates robust anti-tumor activity in mouse carcinoma models

Baiteng Zhao, Lei Wang, Haidong Liu, Suping Huang, Xiao Shang, Tae Han
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1085.
https://doi.org/10.1158/1538-7445.AM2022-1085
Published: 15 June 2022
View article titled, Abstract 1085: PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, demonstrates robust anti-tumor activity in mouse carcinoma models
Journal Articles

Abstract 3112: Metabolic hallmarks of rare renal cell carcinoma patient-derived xenograft models

Manuel Ozambela, Alberto Pieretti, Graciela M. Nogueras Gonzalez, Tapati Maity, Lei Wang, Carolyn De La Cerda, Breanna Alonzo, Luis Segarra, Angelita Alaniz, Priya Rao, Nizar Tannir, Jose A. Karam, Christopher G. Wood, Pavlos Msaouel, Niki M. Zacharias
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3112.
https://doi.org/10.1158/1538-7445.AM2022-3112
Published: 15 June 2022
View article titled, Abstract 3112: Metabolic hallmarks of rare renal cell carcinoma patient-derived xenograft models
Journal Articles

Abstract P1-18-33: Real-world outcomes with palbociclib, abemaciclib and ribociclib; experience of a tertiary oncology centre in the United Kingdom

Lei Wang, Muhammad Ibrahim, Anthony Neal
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P1-18-33.
https://doi.org/10.1158/1538-7445.SABCS21-P1-18-33
Published: 15 February 2022
View article titled, Abstract P1-18-33: Real-world outcomes with palbociclib, abemaciclib and ribociclib; experience of a tertiary oncology centre in the United Kingdom